Clinical trial
Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for…
NCT00403130 · George Albert Fisher, Other · Completed
Key facts
| NCT number | NCT00403130 |
|---|---|
| Title | Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer |
| Official title | Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer |
| Lead sponsor | George Albert Fisher, Other |
| Collaborators | Genentech, Inc. Industry Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Paclitaxel, Bevacizumab |
| Enrollment | 31 |
| Start date | Feb 1, 2006 |
| Primary completion | Sep 1, 2010 |
| Completion | Nov 1, 2012 |
| First posted | Nov 23, 2006 |
| Last update posted | Feb 20, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: